Janney Montgomery Scott LLC Trims Holdings in Masimo Corporation $MASI

Janney Montgomery Scott LLC trimmed its position in Masimo Corporation (NASDAQ:MASI) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,681 shares of the medical equipment provider’s stock after selling 81 shares during the period. Janney Montgomery Scott LLC’s holdings in Masimo were worth $283,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA lifted its holdings in Masimo by 13.4% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider’s stock valued at $327,842,000 after purchasing an additional 232,671 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Masimo by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,673,252 shares of the medical equipment provider’s stock valued at $278,764,000 after purchasing an additional 10,876 shares in the last quarter. Durable Capital Partners LP purchased a new position in Masimo in the 1st quarter valued at about $187,528,000. Alyeska Investment Group L.P. lifted its holdings in Masimo by 24.9% in the 1st quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock valued at $120,374,000 after purchasing an additional 143,899 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Masimo by 8.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock valued at $117,172,000 after purchasing an additional 55,658 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Trading Down 0.3%

NASDAQ MASI opened at $146.78 on Monday. Masimo Corporation has a one year low of $133.70 and a one year high of $194.88. The company’s 50 day moving average price is $145.60 and its 200 day moving average price is $154.57. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The firm has a market capitalization of $7.97 billion, a price-to-earnings ratio of -17.23 and a beta of 1.28.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million for the quarter. On average, sell-side analysts predict that Masimo Corporation will post 4.1 EPS for the current year.

Insider Buying and Selling

In other Masimo news, Director William R. Jellison purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The shares were purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the acquisition, the director owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This represents a 167.60% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 16.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on MASI. BTIG Research restated a “buy” rating and issued a $198.00 target price on shares of Masimo in a report on Thursday, September 11th. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Piper Sandler increased their price objective on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Zacks Research upgraded shares of Masimo from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and an average price target of $194.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.